Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Nora Hennies und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Deutschland GmbH, Werner-Reimers-Straße 2, Bad Homburg vor de Höhe, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To identify the prevalence of cardiovascular disease (CVD) and obesity in patients with type 2 diabetes (T2D) in Germany and to evaluate if antidiabetic treatment patterns varied by comorbidity status. Materials and Methods Patients with T2D (aged ≥18 years) were identified during the study period (2014–2020) from medical claims of 4.5 million publicly insured German residents and divided into different cohorts based on CVD and/or obesity diagnosis. Annual prevalence and incidence were estimated for each study year, while characteristics and treatments were assessed in 2020. Data were extrapolated to the German population by age and sex.
Results
The prevalence of T2D in 2020 was 11.4%. Among patients with T2D, 53.0% had CVD, 39.3% had obesity, and 20.9% had CVD and obesity. Since 2014, CVD increased by 1.4%, obesity by 4.5%, and CVD with obesity by 2.7% in patients with T2D. The incidence of T2D in 2020 was 1.0% (42.9% had CVD, 37.9% had obesity, and 15.8% had CVD and obesity). Among the prevalent T2D population in 2020, 4.9% received glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), 9.7% received sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, and 13.0% received GLP‐1 RAs and/or SGLT2 inhibitors. Of those with CVD, 12.9% received GLP‐1 RAs and/or SGLT2 inhibitors (without CVD, 13.2%). Of those with obesity, 19.4% received GLP‐1RAs and/or SGLT2 inhibitors (without obesity, 9.0%).
Conclusions
In this retrospective claims database study, more than two thirds of patients with T2D also had CVD, obesity, or both CVD and obesity. GLP‐1 RA and SGLT2 inhibitor use remained low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Deutschland GmbH, Werner-Reimers-Straße 2, Bad Homburg vor de Höhe, Germany.
- Scientific Institute for Health Economics and Health System Research (WIG2 GmbH) Markt 8, Leipzig, Germany.
- Department of Medicine I, University Hospital RWTH Aachen, Aachen, Germany.
- Faculty of Economics and Management, Leipzig University, Universitätsstr. 1, Leipzig, Germany.
ORCID-Profile: Nora Hennies, Dirk Müller-Wieland
Förderung
- Eli Lilly and Company
Zitieren
APA
Hennies, N., Görgens, S. W., Killer, J., Otto, T., Richter, L. M., Müller-Wieland, D., & Häckl, D. (2024). Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15931
Vancouver
Hennies N, Görgens SW, Killer J, Otto T, Richter LM, Müller-Wieland D, et al. Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15931
BibTeX
@article{Hennies2024,
author = {Hennies, Nora and Görgens, Sven W and Killer, Jonas and Otto, Thorsten and Richter, Lena M and Müller-Wieland, Dirk and Häckl, Dennis},
title = {Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15931}
}
EUVIMED